Glucotrack, Inc. (GCTK): Nasdaq/NYSE listing notice — Glucotrack receives Nasdaq bid price deficiency notice; has until June 30, 2025 to regain compliance

Glucotrack, Inc.

Bid price closed below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
Company has 180-day cure period until June 30, 2025; can extend if met requirements.
No immediate effect on listing; common stock continues trading under GCTK.
Company expects to cure deficiency, may consider reverse stock split if needed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Glucotrack, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 31, 2024, Nasdaq Stock Market LLC (“Nasdaq”) notified Glucotrack, Inc. (the “Company”) that for at least the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 30, 2025, to regain compliance with the Bid Price Rule. If at any time before June 30, 2025, the bi

View on SEC.gov

Browse all listing & compliance notices →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-052736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.